Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Esperion Therapeutics, Inc.

< Previous 1 2 3 4 Next >
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ASX ESPR
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces $210 Million Convertible Debt Financing
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report Third Quarter 2024 Financial Results on November 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report Second Quarter 2024 Financial Results on August 12
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming BTIG Biotech Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Upcoming June Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.